Animal Venoms as Potential Antitumor Agents Against Leukemia and Lymphoma

TL;DR

Animal venoms may offer new cancer treatments by targeting leukemia and lymphoma cells in ways that reduce side effects.

Contribution

This review highlights venom-derived molecules as novel antitumor agents with mechanisms like apoptosis and immune modulation.

Findings

Venom components like LAAOs and PLA2s induce cancer cell death through oxidative stress and apoptosis.

Peptides such as melittin show selective antitumor activity by targeting cell cycle and survival pathways.

Venom molecules modulate immune responses and inhibit cancer-promoting signaling pathways like NF-κB.

Abstract

Leukemia and lymphoma are types of blood cancer that affect many people worldwide and often have limited treatment options, especially when the disease returns after therapy. In recent years, scientists have explored natural sources to discover new ways to fight these cancers. Animal venoms—such as those from snakes, bees, and scorpions—contain substances that can eliminate cancer cells or prevent them from multiplying. This review examines how certain venom components act on leukemia and lymphoma cells in laboratory studies. These substances can cause cancer cells to lose their function, stop dividing, or undergo controlled cell death. Some venom molecules may also help the immune system recognize and attack cancer cells. Although these findings are mostly from laboratory research and are not yet used in standard medical treatments, they offer promising ideas for developing new medicines. Understanding how these venoms work may lead to therapies that are more effective and have fewer side effects. This work highlights the potential of nature-inspired solutions in the fight against cancer and opens the door to future research that could benefit patients around the world.

Leukemias and lymphomas are hematologic malignancies characterized by complex pathophysiological mechanisms and increasing global incidence. Despite advances in chemotherapy, immunotherapy, and targeted therapies, challenges such as drug resistance and relapse persist, necessitating novel therapeutic strategies. This review explores the cytotoxic potential of venoms derived from snakes, bees, and scorpions against leukemia and lymphoma cells. Numerous venom-derived components, such as L-amino acid oxidases (LAAOs), phospholipases A2 (PLA2s), and peptides like melittin, demonstrate selective antitumor activity through mechanisms involving oxidative stress, apoptosis induction, cell cycle arrest, and immunomodulation. These molecules exert their effects via mitochondrial pathways, caspase activation, and inhibition of pro-survival signaling cascades such as NF-κB and PI3K/Akt. Despite promising preclinical results, the clinical translation of these bioactive compounds remains limited due to challenges in standardization, delivery, and safety profiling. This review highlights recent advances in venom research, summarizes key molecular targets, and discusses future directions to harness venom-derived molecules as innovative therapies for hematological cancers.

Figures